-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Yunnan Plant Pharmaceutical Industry: Production and sale of shoddy drug ginseng injections January 27, 2021, Yunnan Provincial Drug Administration announced the administrative penalty data.
according to article 74 of the Drug Administration Law of the People's Republic of China (2015 edition) and Article 4, paragraph 2, article 5, article 27, paragraph 1 (1), of the Law of the People's Republic of China on Drug Administration, Yunnan Plant Pharmaceutical Co., Ltd. was confiscated illegal products, confiscated illegal income and fined by the Yunnan Drug Administration for the production and sale of shoddy drug ginseng injections.
: Production and sale of clams that do not meet drug standards On January 28, 2021, the Hubei Provincial Drug Administration released information on administrative penalties.
Wuhan Mindetang Chinese medicine tablets Co. , Ltd. because of the production and sale of clams that do not meet the drug standards, by the Three Gorges Public Inspection and Testing Center inspection (report number: 2020 medicine 0449), Wuhan Mindetang Chinese medicine tablets Co. , Ltd. produced batch number 180901 clams do not meet the requirements.
site inspection also found that the enterprise did not in accordance with the "drug production quality management norms" for the batch of clams to leave samples.
the provisions of Article 117, paragraph 2, and Article 126 of the Drug Administration Act (as amended in 2019).
was warned by the Hubei Provincial Drug Administration and within 15 days corrected the failure to concoctor clams in accordance with the Chinese Pharmacopoeia (2015 edition) and the failure to take samples of the products in accordance with the Quality Management Code for Pharmaceutical Production.